-
2
-
-
84871555750
-
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
-
Sorbye H, Welin S, Langer SW et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013;24:152-60.
-
(2013)
Ann Oncol
, vol.24
, pp. 152-160
-
-
Sorbye, H.1
Welin, S.2
Langer, S.W.3
-
3
-
-
0026747929
-
Extr a-pulmonary and pulmonary small-cell carcinoma: Tumor biology, therapy, and outcome
-
Remick SC, Ruckdeschel JC. Extr a-pulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol 1992;20:89-99.
-
(1992)
Med Pediatr Oncol
, vol.20
, pp. 89-99
-
-
Remick, S.C.1
Ruckdeschel, J.C.2
-
4
-
-
4344689150
-
Small cell carcinomas of the gastrointestinal tract: A review
-
Brenner B, Tang LH, Klimstra DS et al. Small cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004; 22: 2730-9.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2730-2739
-
-
Brenner, B.1
Tang, L.H.2
Klimstra, D.S.3
-
5
-
-
46449110634
-
One hundred years after carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
-
Yao JC, Eisner MP, Leary C, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3063-3072
-
-
Yao, J.C.1
Eisner, M.P.2
Leary, C.3
-
6
-
-
1842339356
-
An analysis of 8305 cases of carcinoid tumors
-
Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79:813-29.
-
(1997)
Cancer
, vol.79
, pp. 813-829
-
-
Modlin, I.M.1
Sandor, A.2
-
7
-
-
0035447766
-
Treatment with cisplatin and etoposide in patients with neuroendocrine tumors
-
Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-7.
-
(2001)
Cancer
, vol.92
, pp. 1101-1107
-
-
Fjallskog, M.L.1
Granberg, D.P.2
Welin, S.L.3
-
8
-
-
0025933213
-
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin
-
Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 1991;68:227-32.
-
(1991)
Cancer
, vol.68
, pp. 227-232
-
-
Moertel, C.G.1
Kvols, L.K.2
O'Connell, M.J.3
-
9
-
-
0032734719
-
Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin
-
Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br J Cancer 1999;81:1351-5.
-
(1999)
Br J Cancer
, vol.81
, pp. 1351-1355
-
-
Mitry, E.1
Baudin, E.2
Ducreux, M.3
-
10
-
-
0033840109
-
Chemotherapy in the treatment of neuroendocrine malignant tumors
-
Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000;62 (Suppl 1):73-8.
-
(2000)
Digestion
, vol.62
, Issue.SUPPL. 1
, pp. 73-78
-
-
Rougier, P.1
Mitry, E.2
-
11
-
-
33747061873
-
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network study
-
Hainsworth JD, Thompson DS, Urba WJ, et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2006;24:3548-54.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3548-3554
-
-
Hainsworth, J.D.1
Thompson, D.S.2
Urba, W.J.3
-
12
-
-
0242349455
-
A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma
-
Hou Z, Elasmar A, Lozano R, et al. A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proc Am Soc Clin Oncol 2003;22:375.
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 375
-
-
Hou, Z.1
Elasmar, A.2
Lozano, R.3
-
13
-
-
66149091639
-
A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma
-
Mani M, Shroff RT, Jacobs C, et al. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. J Clin Oncol 2008; 26S:15550.
-
(2008)
J Clin Oncol
, vol.26 S
, pp. 15550
-
-
Mani, M.1
Shroff, R.T.2
Jacobs, C.3
-
14
-
-
33746449124
-
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
-
Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006; 51:1033.
-
(2006)
Dig Dis Sci
, vol.51
, pp. 1033
-
-
Kulke, M.H.1
Wu, B.2
Ryan, D.P.3
-
15
-
-
26844517731
-
Endocrine tumours of the gastrointestinal tract. Introduction: Definition, historical aspects, classification, staging, prognosis and therapeutic options
-
Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005;19:491-505.
-
(2005)
Best Pract Res Clin Gastroenterol
, vol.19
, pp. 491-505
-
-
Arnold, R.1
-
16
-
-
79851500081
-
Everolimus for advanced pancreatic neuroendocrine tumors
-
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
-
(2011)
N Engl J Med
, vol.364
, pp. 514-523
-
-
Yao, J.C.1
Shah, M.H.2
Ito, T.3
-
17
-
-
79851482955
-
Sunitinib Malate for the treatment of pancreatic neuroendocrine tumors
-
Raymond E, Dahan L, Raoul JL, et al. Sunitinib Malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
-
(2011)
N Engl J Med
, vol.364
, pp. 501-513
-
-
Raymond, E.1
Dahan, L.2
Raoul, J.L.3
-
18
-
-
83255167036
-
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study
-
Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-12.
-
(2011)
Lancet
, vol.378
, pp. 2005-2012
-
-
Pavel, M.E.1
Hainsworth, J.D.2
Baudin, E.3
-
19
-
-
84884606524
-
Poorly differentiated neoendocrine tumors
-
In: Yao JC, Hoff PM, Hoff AO, eds. 1st ed. New York: Humana Press
-
Bezerra JE, Riechelamann RP, Hoff PM. Poorly differentiated neoendocrine tumors. In: Yao JC, Hoff PM, Hoff AO, eds. Neuroendocrine tumors. 1st ed. New York: Humana Press; 2011.
-
(2011)
Neuroendocrine tumors
-
-
Bezerra, J.E.1
Riechelamann, R.P.2
Hoff, P.M.3
-
20
-
-
0033797356
-
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
-
Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36.
-
(2000)
Lung Cancer
, vol.30
, pp. 23-36
-
-
Mascaux, C.1
Paesmans, M.2
Berghmans, T.3
-
21
-
-
0024420890
-
Complete remission of refractory small cell carcinoma of the pancreas with cisplatin and etoposide
-
Morant R, Bruckner HW. Complete remission of refractory small cell carcinoma of the pancreas with cisplatin and etoposide. Cancer 1989;64:2007-9.
-
(1989)
Cancer
, vol.64
, pp. 2007-2009
-
-
Morant, R.1
Bruckner, H.W.2
-
22
-
-
0023851785
-
Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small cell lung cancer
-
Einhorn LH, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small cell lung cancer. J Clin Oncol 1988;6:451-6.
-
(1988)
J Clin Oncol
, vol.6
, pp. 451-456
-
-
Einhorn, L.H.1
Crawford, J.2
Birch, R.3
-
23
-
-
0031887545
-
Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer
-
Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 1998; 16:1068-7.
-
(1998)
J Clin Oncol
, vol.16
, pp. 1068-1077
-
-
Kudoh, S.1
Fujiwara, Y.2
Takada, Y.3
-
24
-
-
33646447066
-
Randomized Phase iii trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
-
Hanna N, Bunn PA, Langer C, et al. Randomized Phase iii trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43
-
(2006)
J Clin Oncol
, vol.24
, pp. 2038-2043
-
-
Hanna, N.1
Bunn, P.A.2
Langer, C.3
-
25
-
-
66349102227
-
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensivestage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124
-
Lara PN, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensivestage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2530-2535
-
-
Lara, P.N.1
Natale, R.2
Crowley, J.3
-
26
-
-
79959375226
-
Neuroendocrine tumors of the stomach: Chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma
-
Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 2011;14:161-5.
-
(2011)
Gastric Cancer
, vol.14
, pp. 161-165
-
-
Okita, N.T.1
Kato, K.2
Takahari, D.3
-
27
-
-
84865106659
-
Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas
-
Nakano K, Takahashi S, Yuasa T, et al. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas. Jpn J Clin Oncol 2012;42:697-703.
-
(2012)
Jpn J Clin Oncol
, vol.42
, pp. 697-703
-
-
Nakano, K.1
Takahashi, S.2
Yuasa, T.3
-
28
-
-
84858659147
-
Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system
-
Yamaguchi T, Machida N, Kasuga A, et al. Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system. J Clin Oncol 2012;30:274.
-
(2012)
J Clin Oncol
, vol.30
, pp. 274
-
-
Yamaguchi, T.1
McHida, N.2
Kasuga, A.3
-
29
-
-
33847098794
-
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing lowgrade and hogh-grade neuroendocrine tumors?
-
Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing lowgrade and hogh-grade neuroendocrine tumors? Cancer Chemother Pharmacol 2007;59: 637-42.
-
(2007)
Cancer Chemother Pharmacol
, vol.59
, pp. 637-642
-
-
Bajetta, E.1
Catena, L.2
Procopio, G.3
-
30
-
-
84884622485
-
Combination of capecitabine and oxaliplatin (CAPOX) is an effective option for the treatment of neuroendocrine tumors (NET). Poster presentation session
-
Stockholm, Sweden
-
Ferrarotto R, Testa L, Riechelmann RP, et al. Combination of capecitabine and oxaliplatin (CAPOX) is an effective option for the treatment of neuroendocrine tumors (NET). Poster presentation session. Meeting of the European Society of Medical Oncology, 2011, Stockholm, Sweden.
-
(2011)
Meeting of the European Society of Medical Oncology
-
-
Ferrarotto, R.1
Testa, L.2
Riechelmann, R.P.3
-
31
-
-
33747061873
-
Phase II trial of paclitaxel, parboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network Study
-
Hainsworth JD, Spigel DR, Litchy S, et al. Phase II trial of paclitaxel, parboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006;24:3548.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3548
-
-
Hainsworth, J.D.1
Spigel, D.R.2
Litchy, S.3
|